세계 RNA 분석 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 기술별, 용도별, 최종 용도별, 지역별 부문, 경쟁(2020-2030년)
RNA Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Product, By Technology (Real Time-PCR, Microarray, Sequencing, others), By Application, By End-use, By Region and Competition, 2020-2030F
상품코드:1691713
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 184 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
RNA 분석 세계 시장 규모는 2024년에 96억 8,000만 달러로 평가되었고, 예측 기간 중 CAGR은 9.78%를 나타낼 전망이며, 2030년에는 143억 8,000만 달러에 달할 것으로 예측되고 있습니다.
RNA 분석은 RNA(리보 핵산) 분자의 구조, 기능, 제어 및 발현 패턴을 이해하기위한 연구를 포함한 분자 생물학 및 유전체학의 광범위한 분야입니다. RNA는 분자 생물학의 센트럴 도그마에서 중요한 분자이며, DNA와 단백질 합성의 중간 역할을 합니다. RNA 분석은 RNA가 세포와 유기체에서 수행하는 다양한 역할을 밝히기 위한 다양한 기술과 접근법을 다룹니다. RNA 분석은 mRNA 전사 산물에서 다른 엑손을 포함하거나 제외하는 대체 스플라이싱 이벤트를 밝힐 수 있습니다. 이 과정은 하나의 유전자로부터 다수의 단백질 이소형을 생성합니다. RNA-Seq는 alternative splicing을 조사하는데 특히 유용합니다. 임상 장소에서 RNA 분석은 감염에 대한 바이러스 RNA의 검출 및 치료 결정의 지침이 되는 유전자 발현 패턴의 평가와 같은 진단 목적으로 사용됩니다. 차세대 시퀀싱(NGS)과 단일 셀 RNA 시퀀싱(scRNA-seq)과 같은 RNA 시퀀싱 기술의 끊임없는 진보로 RNA 분석의 기능이 확대되고 있습니다. 시퀀싱 정확도, 처리량 향상 및 비용 절감으로 연구 및 임상 응용 분야에서 채택이 진행되고 있습니다. RNA 분석은 암 연구에 널리 사용되고 있으며, 암 바이오마커의 동정, 종양의 불균일성의 연구, 표적 요법의 개발에 도움이 되고 있습니다. 암의 유병률 증가로 RNA 기반 진단 및 치료 접근법에 대한 수요가 증가하고 있습니다.mRNA 백신과 RNA 간섭(RNAi) 요법을 포함한 RNA 기반 치료제의 개발은 큰 기세를 얻고 있습니다. 이 때문에 치료 설계 최적화 및 치료 반응 모니터링을 위해 RNA 분석에 대한 관심이 높아지고 있습니다. RNA 분석은 감염의 감시 및 모니터링에 중요한 역할을 합니다. COVID-19의 유행은 RNA 기반 진단의 중요성과 신속하고 정확한 병원체 검출의 필요성을 돋보이게 했습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
96억 8,000만 달러
시장 규모 : 2030년
143억 8,000만 달러
CAGR : 2025-2030년
9.78%
급성장 부문
실시간 PCR(qPCR)
최대 시장
북미
시장 성장 촉진요인
RNA 시퀀싱 기술의 발전
주요 시장 과제
단일 셀 RNA 시퀀싱의 복잡성
주요 시장 동향
바이오인포매틱스 및 데이터 분석
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 RNA 분석 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
제품별(키트 및 시약, 서비스, 기기)
기술별(실시간 PCR(qPCR), 마이크로어레이, 시퀀싱, 기타)
용도별(후성 유전학, 감염증과 병인, RNA 선택적 스 가격, RNA 구조와 분자 동역학, RNA 치료제 개발과 제공)
최종 용도별(정부기관 및 학술센터, 제약 및 생명공학기업, 병원 및 진료소 등)
지역별
기업별(2024)
시장 맵
제6장 북미의 RNA 분석 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
캐나다
멕시코
제7장 유럽의 RNA 분석 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 RNA 분석 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양: 국가별 분석
인도
일본
한국
호주
제9장 남미의 RNA 분석 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 RNA 분석 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
합병과 인수(해당하는 경우)
제품 발매(해당하는 경우)
최근 동향
제13장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd
Illumina, Inc.
QIAGEN NV
Thermo Fisher Scientific, Inc.
Eurofins Scientific
Merck KGaA
Bio-Rad Laboratories, Inc.
Pacific Bioscience of California, Inc.
Affymetrix, Inc.
제15장 전략적 제안
제16장 기업 소개와 면책사항
SHW
영문 목차
영문목차
Global RNA Analysis Market was valued at USD 9.68 Billion in 2024 and is expected to reach USD 14.38 Billion by 2030 with a CAGR of 9.78% during the forecast period. RNA analysis is a broad field of molecular biology and genomics that involves the study of RNA (ribonucleic acid) molecules to understand their structure, function, regulation, and expression patterns. RNA is a crucial molecule in the central dogma of molecular biology, serving as an intermediary between DNA and protein synthesis. RNA analysis encompasses various techniques and approaches aimed at elucidating the diverse roles that RNA plays within cells and organisms. RNA analysis can reveal alternative splicing events, where different exons are included or excluded from mRNA transcripts. This process generates multiple protein isoforms from a single gene. RNA-Seq is particularly valuable for studying alternative splicing. In clinical settings, RNA analysis is used for diagnostic purposes, such as detecting viral RNA in infectious diseases or assessing gene expression patterns to guide treatment decisions. Continuous advancements in RNA sequencing technologies, such as next-generation sequencing (NGS) and single-cell RNA sequencing (scRNA-seq), have expanded the capabilities of RNA analysis. Improved sequencing accuracy, throughput, and reduced costs are driving adoption in research and clinical applications. RNA analysis is widely used in oncology research, where it aids in identifying cancer biomarkers, studying tumor heterogeneity, and developing targeted therapies. The increasing prevalence of cancer drives the demand for RNA-based diagnostic and therapeutic approaches. The development of RNA-based therapeutics, including mRNA vaccines and RNA interference (RNAi) therapies, has gained significant momentum. This has led to increased interest in RNA analysis for optimizing therapeutic design and monitoring treatment responses. RNA analysis plays a crucial role in the surveillance and monitoring of infectious diseases. The COVID-19 pandemic highlighted the importance of RNA-based diagnostics and the need for rapid and accurate pathogen detection.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 9.68 Billion
Market Size 2030
USD 14.38 Billion
CAGR 2025-2030
9.78%
Fastest Growing Segment
Real-time-PCR (qPCR)
Largest Market
North America
Key Market Drivers
Advancements in RNA Sequencing Technologies
Next-Generation Sequencing (NGS) platforms such as Illumina's HiSeq and NovaSeq, have become the workhorses of RNA-Seq. These platforms offer high-throughput sequencing with massive parallel processing, allowing researchers to analyze thousands to millions of RNA molecules simultaneously. NGS has significantly reduced the cost of sequencing and increased the speed of data generation. Single-Cell RNA Sequencing (scRNA-Seq) enables the analysis of gene expression at the single-cell level, revealing cellular heterogeneity within tissues and organisms. This technology has advanced our understanding of developmental biology, immunology, and disease progression. Innovations in microfluidics and barcoding have made scRNA-Seq more accessible and efficient. Traditional short-read sequencing platforms can struggle to accurately assemble long transcripts and resolve complex gene structures. Long-read sequencing technologies, such as Pacific Biosciences' SMRT sequencing and Oxford Nanopore Technologies' nanopore sequencing, produce longer sequencing reads. In July 2024, Biostate AI introduced advanced RNA sequencing and analysis tools, including Total RNA Sequencing technology. This innovation utilizes the company's patent-pending Barcode-Integrated Reverse Transcription (BIRT) to analyze all RNA types, including non-coding RNA species. Biostate AI's technology enhances researchers' ability to understand gene expression and regulation, offering valuable insights into disease mechanisms and potential therapeutic targets.
Key Market Challenges
Single-Cell RNA Sequencing Complexity
Single-cell RNA sequencing (scRNA-Seq) is a powerful and transformative technology that has revolutionized our understanding of cellular heterogeneity and gene expression at the single-cell level. scRNA-Seq generates vast amounts of data, with each cell representing a data point. Analyzing and managing this high-dimensional data is computationally intensive and requires specialized bioinformatics tools and expertise. Ensuring data quality is challenging in scRNA-Seq due to potential sources of technical variability, such as cell capture efficiency, library preparation, and sequencing biases. Quality control steps are critical to identify and mitigate these issues. Normalizing scRNA-Seq data to account for differences in sequencing depth and library size between cells is a complex task. Various normalization methods have been developed, but choosing the appropriate one for a given dataset can be challenging. Batch effects can arise when cells are processed in different batches or on different platforms. These batch effects can confound the analysis and interpretation of scRNA-Seq data. Strategies for batch correction are an ongoing area of research. scRNA-Seq can inadvertently capture more than one cell in a single droplet or well, leading to cell doublets or multiplets. Identifying and removing these artifacts is crucial for accurate analysis. Not all RNA molecules in a cell are captured during scRNA-Seq. The efficiency of capturing RNA varies which can result in a skewed representation of gene expression levels. Accurate cell type identification and annotation can be challenging, especially in heterogeneous tissues. Defining cell types and subtypes based on gene expression profiles requires careful curation and integration with existing knowledge. Identifying and characterizing rare cell populations can be difficult due to the limited number of cells and transcripts available for analysis.
Key Market Trends
Bioinformatics and Data Analysis
With the explosion in RNA-Seq data volume, efficient data management and storage solutions are essential. Bioinformatics tools help researchers organize, store, and retrieve large datasets. RNA-Seq data often require preprocessing steps to remove noise, correct for biases, and normalize data. Bioinformatics pipelines are used to perform these essential data preprocessing tasks. In May 2023, ReNAgade Therapeutics emerged after securing $300 million in Series A funding, driven by the potential of RNA technology. The company is led by a team of industry experts, including former Moderna executives, positioning it for innovation and growth in the RNA-based therapeutics sector.
Quality control metrics and algorithms are employed to assess the quality of RNA-Seq data and samples. Identifying and addressing issues early in the analysis process is critical to obtaining reliable results. Bioinformatics tools align sequencing reads to reference genomes or transcriptomes. Accurate alignment is crucial for quantifying gene expression levels and identifying variants. Bioinformatics algorithms are used to quantify gene expression levels and perform differential expression analysis to identify genes that are differentially expressed between conditions (e.g., disease vs. control). Tools and methods are developed to analyze alternative splicing patterns, providing insights into gene regulation and isoform diversity. Specialized bioinformatics pipelines are tailored to the unique challenges of single-cell RNA-Seq data, including cell clustering, dimensionality reduction, and cell type annotation.
Key Market Players
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd
Illumina, Inc.
QIAGEN NV
Thermo Fisher Scientific, Inc.
Eurofins Scientific
Merck KgaA
Bio-Rad Laboratories, Inc.
Pacific Bioscience of California, Inc.
Affymetrix, Inc.
Report Scope:
In this report, the Global RNA Analysis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
RNA Analysis Market, By Product:
Kits & Reagents
Services
Instruments
RNA Analysis Market, By Technology:
Real Time-PCR (qPCR)
Microarray
Sequencing
others
RNA Analysis Market, By Application:
Epigenetics
Infectious Diseases & Pathogenesis
Alternative RNA Splicing
RNA Structure & Molecular Dynamics
Development & Delivery of RNA Therapeutics
RNA Analysis Market, By End-User:
Government Institutes & Academic Centers
Pharmaceutical & Biotechnology Companies
Hospitals & Clinics
others
RNA Analysis Market, By region:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
South Korea
Australia
Japan
Europe
Germany
France
United Kingdom
Spain
Italy
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global RNA Analysis Market.
Available Customizations:
Global RNA Analysis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global RNA Analysis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Kits & Reagents, Services, Instruments)
5.2.2. By Technology (Real Time-PCR (qPCR), Microarray, Sequencing, Others)
5.2.3. By Application (Epigenetics, Infectious Diseases & Pathogenesis, Alternative RNA Splicing, RNA Structure & Molecular Dynamics, Development & Delivery of RNA Therapeutics)
